Insulin-Like Growth Factor Receptor

Journal of Thoracic Oncology

Volumn 6, Issue 11, 2011, Pages S1799-S1800

  Blumenschein, George ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; SOMATOMEDIN RECEPTOR;

ARTICLE; CLINICAL TRIAL (TOPIC); DRUG ANTAGONISM; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; METABOLISM;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; HUMANS; LUNG NEOPLASMS; RECEPTORS, SOMATOMEDIN;

EID: 84857071189     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/01.JTO.0000407563.14653.0c     Document Type: Article

References (10)

1. Yu, H, Spitz, MR, Mistry, J, et al. Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J Natl Cancer Inst 91 (1999), 151–156.
2. Gridelli, C, Rossi, A, Bareschino, MA, et al. The potential role of insulin-like growth factor receptor inhibitors in the treatment of advanced non-small cell lung cancer. Expert Opin Invest Drugs 19 (2010), 631–639.
3. Rowinsky, EK, Beeram, M, Hammond, LA, et al. A phase I and pharmacokinetic study of pemetrexed plus irinotecan in patients with advanced solid malignancies. Clin Cancer Res 13 (2007), 532–539.
4. Tolcher, AW, Sarantopoulos, J, Patnaik, A, et al. Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J Clin Oncol 27 (2009), 5800–5807.
5. Lorigan, P, Soria, J, Stephenson, J, et al. Safety and pharmacokinetics of first-line AMG 479 (Mab to IGF1R) or AMG 102 (Mab to HGF/SF) with platinum-based chemotherapy in extensive-stage small cell lung cancer (SCLC). Ann Oncol 21 (2010), viii122–viii161.
6. Scartozzi, M, Bianconi, M, Maccaroni, E, et al. Dalotuzumab, a recombinant humanized mAb targeted against IGFR1 for the treatment of cancer. Curr Opin Mol Ther 12 (2010), 361–371.
7. Macaulay, VM, Middleton, MR, Eckhardt, SG, et al. Phase I study of OSI-906, dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) in combination with erlotinib (E) in patients with advanced solid tumors. J Clin Oncol, 28(Suppl), 2010 abstract 3016.
8. Desai, J, Solomon, BJ, Davis, ID, et al. Phase I dose-escalation study of daily BMS-754807, an oral, dual IGF-1R/insulin receptor (IR) inhibitor in subjects with solid tumors. J Clin Oncol, 28(Suppl), 2010 abstract 3104.
9. Chu QS-C, Kim SW, Ellis PM, et al. BMS-754807, an oral dual IGF-1R/Insulin receptor (IR) inhibitor: initial results from a phase 1 dose- and schedule-finding study in combination with carboplatin/paclitaxel in subjects with solid tumors. 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. Berlin, Germany, 2010.
10. Karp, DD, Paz-Ares, LG, Novello, S, et al. Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J Clin Oncol 27 (2009), 2516–2522.